A5065724405- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- Hepatitis Viruses Studies and Epidemiology
- Cytomegalovirus and herpesvirus research
- Liver Disease and Transplantation
- Gut microbiota and health
- Bacterial Identification and Susceptibility Testing
- Folate and B Vitamins Research
- Liver Diseases and Immunity
- Hepatocellular Carcinoma Treatment and Prognosis
- Antimicrobial Resistance in Staphylococcus
- Drug-Induced Hepatotoxicity and Protection
- Drug Transport and Resistance Mechanisms
- Bacterial biofilms and quorum sensing
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV/AIDS Research and Interventions
- Metabolism and Genetic Disorders
- Diabetes and associated disorders
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 and COVID-19 Research
- Diet and metabolism studies
- Diet, Metabolism, and Disease
- Parasitic infections in humans and animals
Toronto General Hospital
2015-2025
University of Toronto
2016-2025
University Health Network
2015-2024
Toronto Liver Centre
2017-2024
University of Hong Kong
2022-2023
Queen Mary Hospital
2022-2023
Health Net
2019
University of Manitoba
2019
Janssen (Belgium)
2019
McGill University
2019
Despite evidence that the intestinal microbiota (IM) is involved in pathogenesis of obesity, IM composition patients with nonalcoholic fatty liver disease (NAFLD) has not been well characterized. This prospective, cross-sectional study was aimed at identifying differences between adults biopsy-proven NAFLD (simple steatosis [SS] or steatohepatitis [NASH]) and living donors as healthy controls (HC). Fifty subjects were included: 11 SS, 22 NASH, 17 HC. One stool sample collected from each...
The incidence and risk factors for adefovir-resistant HBV have not been clearly defined.To characterize the virologic response to adefovir, determine rate of adefovir resistance explore associated with initial (IVR) resistance.All hepatitis B patients who received > or =6 months at our center were prospectively monitored resistance.Forty three included; mean treatment duration was 18 (range 6-45). Thirty four (79%) had prior lamivudine. IVR observed in 44% higher pretreatment ALT (P = 0.05)...
Background & Aims Non-alcoholic fatty liver disease (NAFLD) is characterized by dysbiosis. The bidirectional effects between intestinal microbiota (IM) and bile acids (BA) suggest that dysbiosis may be accompanied an altered acid homeostasis, which in turn can contribute to the metabolic dysregulation seen NAFLD. This study sought examine BA homeostasis patients with NAFLD relate IM data. Methods was a prospective, cross-sectional of adults biopsy-confirmed (non-alcoholic liver: NAFL or...
Background & AimsPatients chronically infected with the hepatitis B virus rarely achieve loss of serum surface antigen (HBsAg) standard care. We evaluated HBsAg in patients receiving combination tenofovir disoproxil fumarate (TDF) and peginterferon α-2a (peginterferon) for a finite duration randomized trial.MethodsIn an open-label, active-controlled study, 740 chronic were randomly assigned to receive TDF plus 48 weeks (group A), 16 followed by 32 B), 120 C), or D). The primary end point was...
In nonalcoholic fatty liver disease, hepatic gene expression and acid (FA) composition have been reported independently, but a comprehensive profiling in relation to FA is lacking. The aim was assess this relationship. cross-sectional study, (Illumina Microarray) first compared among 20 patients with simple steatosis (SS), 19 steatohepatitis (NASH), 24 healthy controls. total lipids between SS NASH, associations FAs were examined. Gene differed mainly controls (SS NASH), including genes...
BACKGROUND Efficacy trials have shown that antiviral therapy improves the outcomes of patients with chronic hepatitis B virus (HBV) infection. However, prospective data regarding effect on incidence hepatocellular carcinoma (HCC), especially among without cirrhosis, are limited. The authors examined impact tenofovir disoproxil fumarate (TDF) HCC using a validated prediction model. METHODS in treated TDF was obtained pivotal registration studies after 384 weeks follow‐up. predicted risk...
Accumulation of activated immune cells results in nonspecific hepatocyte killing chronic hepatitis B (CHB), leading to fibrosis and cirrhosis. This study aims understand the underlying mechanisms humans define whether these are driven by widespread activation or a subpopulation cells. We enrolled CHB patients with active liver damage receive antiviral therapy performed longitudinal sampling using fine-needle aspiration investigate pathogenesis human liver. Single-cell sequencing total...
Multi-drug resistant hepatitis B virus (HBV) has been reported in patients who received sequential antiviral therapy. In vitro studies showed that HBV constructs with mutations to lamivudine and adefovir have marked reduction sensitivity combination of adefovir, whereas either drug remain sensitive the other drug. We conducted this study determine whether conferring resistance multiple agents co-locate on same genome vivo describe evolution these mutations. Sera from six had found multi-drug...
Although most patients with chronic hepatitis B (CHB) reach effective virological suppression long-term nucleos(t)ide analogues (NA) therapy, some might not need to continue treatment for life. In this randomised, controlled, phase IV trial, we evaluated off-therapy outcomes in after discontinuing NA therapy.Patients who had received therapy ≥1 year and achieved (hepatitis e antigen (HBeAg) seroconversion combined undetectable virus (HBV) DNA ≥12 months HBeAg-positive or HBV ≥36...
INTRODUCTION: The results from 2 phase 3 studies, through years, in chronic hepatitis B infection showed tenofovir alafenamide (TAF) had similar efficacy to disoproxil fumarate (TDF) with superior renal and bone safety. We report updated 5 years. METHODS: Patients HBeAg-negative or HBeAg-positive without compensated cirrhosis were randomized (2:1) TAF 25 mg TDF 300 once daily double-blind (DB) fashion for up followed by open-label (OL) 8 Efficacy (antiviral, biochemical, serologic),...
Lamivudine has demonstrated efficacy for the treatment of hepatitis B e antigen-negative chronic (e-CHB). However, withdrawal after 1 year been associated with a high rate relapse while long-term is increasing risks drug resistance. We report our experience 50 Chinese-Canadian patients e-CHB. All received lamivudine 2 years. Treatment was withdrawn at month 24 in who had undetectable virus (HBV) DNA by PCR and normal aminotransferases during second therapy. HBV genotype or C. Biochemical...
Abstract Background: There is growing evidence that nonalcoholic fatty liver disease (NAFLD) associated with perturbations in lipid metabolism. Liver phospholipid and acid composition have been shown to be altered NAFLD. However, detailed profiles of circulating lipids the pathogenesis NAFLD are lacking. Objective: Therefore, objective present study was examine potential mechanisms related hepatic gene expression between biopsy-proven simple steatosis (SS), steatohepatitis (NASH) healthy...